These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

458 related articles for article (PubMed ID: 23984829)

  • 1. Drug analogs of COX-2 selective inhibitors lumiracoxib and valdecoxib derived from in silico search and optimization.
    Bartzatt R
    Antiinflamm Antiallergy Agents Med Chem; 2014 Mar; 13(1):17-28. PubMed ID: 23984829
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical pharmacology of lumiracoxib, a second-generation cyclooxygenase 2 selective inhibitor.
    Bannwarth B; Berenbaum F
    Expert Opin Investig Drugs; 2005 Apr; 14(4):521-33. PubMed ID: 15882125
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Valdecoxib: a review.
    Chavez ML; DeKorte CJ
    Clin Ther; 2003 Mar; 25(3):817-51. PubMed ID: 12852704
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Valdecoxib is as effective as diclofenac in the management of rheumatoid arthritis with a lower incidence of gastroduodenal ulcers: results of a 26-week trial.
    Pavelka K; Recker DP; Verburg KM
    Rheumatology (Oxford); 2003 Oct; 42(10):1207-15. PubMed ID: 12810937
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation.
    Chen YF; Jobanputra P; Barton P; Bryan S; Fry-Smith A; Harris G; Taylor RS
    Health Technol Assess; 2008 Apr; 12(11):1-278, iii. PubMed ID: 18405470
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Valdecoxib is associated with improved dyspepsia-related health compared with nonspecific NSAIDs in patients with osteoarthritis or rheumatoid arthritis.
    Rabeneck L; Goldstein JL; Vu A; Mayne TJ; Rublee DA
    Am J Gastroenterol; 2005 May; 100(5):1043-50. PubMed ID: 15842577
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Valdecoxib (Bextra)].
    Scheen AJ; Malaise M
    Rev Med Liege; 2004 Apr; 59(4):251-4. PubMed ID: 15182039
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Valdecoxib.
    Baker DE
    Rev Gastroenterol Disord; 2002; 2(3):116-25. PubMed ID: 12227215
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Review article: The pharmacological properties and clinical use of valdecoxib, a new cyclo-oxygenase-2-selective inhibitor.
    Alsalameh S; Burian M; Mahr G; Woodcock BG; Geisslinger G
    Aliment Pharmacol Ther; 2003 Feb; 17(4):489-501. PubMed ID: 12622757
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Clinical pharmacology of the selective COX-2 inhibitors].
    Burian M; Geisslinger G
    Orthopade; 2003 Dec; 32(12):1078-87. PubMed ID: 14655004
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-hyperalgesic activity of the cox-2 inhibitor lumiracoxib in a model of bone cancer pain in the rat.
    Fox A; Medhurst S; Courade JP; Glatt M; Dawson J; Urban L; Bevan S; Gonzalez I
    Pain; 2004 Jan; 107(1-2):33-40. PubMed ID: 14715386
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chemical and biological investigation of N-hydroxy-valdecoxib: An active metabolite of valdecoxib.
    Erdélyi P; Fodor T; Varga AK; Czugler M; Gere A; Fischer J
    Bioorg Med Chem; 2008 May; 16(9):5322-30. PubMed ID: 18353655
    [TBL] [Abstract][Full Text] [Related]  

  • 13. COX-2 selective inhibitors in the treatment of arthritis: a rheumatologist perspective.
    Hochberg MC
    Curr Top Med Chem; 2005; 5(5):443-8. PubMed ID: 15974939
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of the cyclooxygenase-2 specific inhibitor valdecoxib versus nonsteroidal antiinflammatory agents and placebo on cardiovascular thrombotic events in patients with arthritis.
    White WB; Strand V; Roberts R; Whelton A
    Am J Ther; 2004; 11(4):244-50. PubMed ID: 15266215
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Valdecoxib: a review of its use in the management of osteoarthritis, rheumatoid arthritis, dysmenorrhoea and acute pain.
    Fenton C; Keating GM; Wagstaff AJ
    Drugs; 2004; 64(11):1231-61. PubMed ID: 15161329
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preclinical pharmacology of lumiracoxib: a novel selective inhibitor of cyclooxygenase-2.
    Esser R; Berry C; Du Z; Dawson J; Fox A; Fujimoto RA; Haston W; Kimble EF; Koehler J; Peppard J; Quadros E; Quintavalla J; Toscano K; Urban L; van Duzer J; Zhang X; Zhou S; Marshall PJ
    Br J Pharmacol; 2005 Feb; 144(4):538-50. PubMed ID: 15655513
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Meloxicam and selective COX-2 inhibitors in the management of pain in the palliative care population.
    Smith HS; Baird W
    Am J Hosp Palliat Care; 2003; 20(4):297-306. PubMed ID: 12911075
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Valdecoxib (Bextra)--a new cox-2 inhibitor.
    Med Lett Drugs Ther; 2002 Apr; 44(1129):39-40. PubMed ID: 11981510
    [No Abstract]   [Full Text] [Related]  

  • 19. Molecular determinants for the selective inhibition of cyclooxygenase-2 by lumiracoxib.
    Blobaum AL; Marnett LJ
    J Biol Chem; 2007 Jun; 282(22):16379-90. PubMed ID: 17434872
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reduced incidence of upper gastrointestinal ulcer complications with the COX-2 selective inhibitor, valdecoxib.
    Goldstein JL; Eisen GM; Agrawal N; Stenson WF; Kent JD; Verburg KM
    Aliment Pharmacol Ther; 2004 Sep; 20(5):527-38. PubMed ID: 15339324
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.